{"id":1692,"date":"2016-12-08T12:09:55","date_gmt":"2016-12-08T12:09:55","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1692"},"modified":"2021-07-24T12:56:35","modified_gmt":"2021-07-24T07:26:35","slug":"the-business-cocktail-6","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6","title":{"rendered":"Novartis joins; Sanofi weighs Actelion; Valeant and Takeda&#8217;s $10B deal; Astellas scouts pipeline"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d84a9914e63\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d84a9914e63\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6\/#With_496M_CNS_sale_Novartis_joins_other_Pharma_companies_casting_off_tired_meds\" >With $496M CNS sale, Novartis joins other Pharma companies casting off tired meds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6\/#Sanofi_weighs_Actelion_offer_to_compete_with_J_Js_27B\" >Sanofi weighs Actelion offer to compete with J&amp;J&#8217;s $27B<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6\/#Valeant_and_Takedas_10B_Salix_deal_talks_scuttled_by_price_squabbles\" >Valeant and Takeda&#8217;s $10B Salix deal talks scuttled by price squabbles<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6\/#Astellas_scouts_pipeline_buys_for_post-Xtandi_future\" >Astellas scouts pipeline buys for post-Xtandi future<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"With_496M_CNS_sale_Novartis_joins_other_Pharma_companies_casting_off_tired_meds\"><\/span>With $496M CNS sale, Novartis joins other Pharma companies casting off tired meds<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs, including Ritalin for attention deficit disorder and Exelon patch for Alzheimer\u2019s. The portfolio could bring in as much as $496 million, and potential buyers include Endo, Mallinckrodt and generic drug makers. Novartis is far from the only company thinking along those lines. AstraZeneca, in fact, has turned asset selling into a cottage industry, casting off the international rights to two heart-disease drugs for $500 million earlier this year, and before that raising nearly $1 billion in a string of out-licensing deals.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Sanofi_weighs_Actelion_offer_to_compete_with_J_Js_27B\"><\/span>Sanofi weighs Actelion offer to compete with J&amp;J&#8217;s $27B<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Reports are floating around claiming that Sanofi is offering up to $27 billion to a so-far unresponsive Actelion that is being pursued by J&amp;J. Sources claim that Sanofi is weighing a counterbid, which presumably would have to top $27 billion. Sanofi is working with financial advisers on a potential offer, and it has told Actelion that it\u2019s interested. It hasn\u2019t yet made a formal move or even decided whether to make an offer, However. Sanofi hasn\u2019t yet commented on the reports. J&amp;J is said to be aiming to strike a deal before Christmas, so the process could move quickly from here if nothing else happens. And with a $27 billion price tag, among the largest of 2016, Actelion will be a closely watched target along the way.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Valeant_and_Takedas_10B_Salix_deal_talks_scuttled_by_price_squabbles\"><\/span>Valeant and Takeda&#8217;s $10B Salix deal talks scuttled by price squabbles<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Talks have broken down at the last minute because of disagreements over price for Valeant\u2019s $10 billion plan to sell its Salix business to Takeda. Takeda, which has reportedly tried multiple times to get its hands on Salix\u2014first as a bidder in the auction Valeant eventually won, and earlier this year with an offer to buy the whole Valeant company\u2014wanted to shell out a lower sum for the GI business. The portfolio has underperformed lately, as many of Valeant\u2019s key meds have, compounding the problems of a company that\u2019s already faced channel-stuffing allegations, a slew of investigations, political pricing pushback and debt-default worries from investors. While there\u2019s still a chance talks could be restarted, Valeant has already decided to move forward with plans to build Salix up on its own\u2014and it\u2019s already announced some of those plans to the public, too.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Astellas_scouts_pipeline_buys_for_post-Xtandi_future\"><\/span>Astellas scouts pipeline buys for post-Xtandi future<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Having built a fortune on a lucrative Xtandi partnering deal, Astellas is scouting for a new round of assets to deliver growth in its next chapter. The Japanese drug maker is joining the likes of larger companies such as Gilead, Johnson &amp; Johnson and Sanofi in biopharma\u2019s active M&amp;A arena. Astellas is scouting for buys in immuno-oncology, Bloomberg reported, and has identified muscular diseases and ophthalmology as potential expansion areas. It\u2019s also working to refocus and sell assets that aren\u2019t central to its plans. Facing a 2019 patent cliff, Astellas has about $3.6 billion in cash to help finance one or more acquisitions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>With $496M CNS sale, Novartis joins other Pharma companies casting off tired meds The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs, including Ritalin for attention deficit disorder and Exelon patch for Alzheimer\u2019s. The portfolio could bring in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1033,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[686,684,96,683,423,451,469,533,554,685],"industry":[17225],"therapeutic_areas":[17229,17228],"class_list":["post-1692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-actelion","tag-astellas","tag-astrazeneca","tag-mergers-and-acquisitions","tag-novartis","tag-partnerships","tag-pharmaceutical-companies","tag-sanofi","tag-takeda","tag-valeant","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novartis joins; Sanofi weighs Actelion; Valeant and Takeda&#039;s $10B deal<\/title>\n<meta name=\"description\" content=\"The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs...\/\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis joins; Sanofi weighs Actelion; Valeant and Takeda&#039;s $10B deal\" \/>\n<meta property=\"og:description\" content=\"The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs...\/\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-08T12:09:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"256\" \/>\n\t<meta property=\"og:image:height\" content=\"196\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal","description":"The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs...\/","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6","og_locale":"en_US","og_type":"article","og_title":"Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal","og_description":"The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs...\/","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-12-08T12:09:55+00:00","article_modified_time":"2021-07-24T07:26:35+00:00","og_image":[{"width":256,"height":196,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6","name":"Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","datePublished":"2016-12-08T12:09:55+00:00","dateModified":"2021-07-24T07:26:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs...\/","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-6#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","width":256,"height":196},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/06175101\/mergacq_opt.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Actelion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Astellas<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mergers and Acquisitions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Partnerships<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Valeant<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Actelion<\/span>","<span class=\"advgb-post-tax-term\">Astellas<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Mergers and Acquisitions<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Partnerships<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical companies<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>","<span class=\"advgb-post-tax-term\">Valeant<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 8, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 8, 2016 12:09 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1692"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1692\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1033"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1692"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1692"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}